GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
D

Dogwood Therapeutics DWTX · USD

Health Care · US listing · 🇺🇸 United States

Compare

1.06

-1.85%

Close of 19 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Dogwood Therapeutics — daily DWTX Delayed
Market value
$1.3m
Last close × shares
Volume
126.4k
Shares, 19 Nov 2026

About Dogwood Therapeutics

From its filings with the US Securities and Exchange Commission

SEC filings

Dogwood Therapeutics is based in Alpharetta, Georgia and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker DWTX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $34.3m. At that date it held total assets of $90.2m and shareholders' equity of $74.9m.

In its own words

We are a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy. Following the closing of the Combination described below, we became the sole owner of Pharmagesic (Holdings) Inc. (“Pharmagesic”) and their wholly owned subsidiary, Wex Pharmaceuticals, Inc. (“Wex”), and Wex’s wholly owned subsidiaries, IWT Bio, Inc. (“IWT”), Wex Medical Corporation (“WMC”), and Wex Medical Limited (“WML”).

Our pipeline is focused on treating chronic neuropathic pain and neuropathy. Our Halneuron® Nav1.7 modulation program is intended to treat chronic and acute pain disorders. Our recently licensed SP16 program is centered on a cell signaling molecule that has shown early promise in treating neuropathy and nerve damage. The Halneuron® program is a proprietary non-opioid Nav1.7 analgesic program centered on voltage-gated sodium channel modulation, a mechanism known to be effective for reducing pain. SP16 is the focus of a planned Phase 1b study that is fully funded through a research grant supplied by the National Cancer Institute, with patient enrollment projected to start in mid-2026.

Quoted from its 10-K, filed 18 Mar 2026. Read the filing on SEC.gov ↗

More about Dogwood Therapeutics →

Latest on Dogwood Therapeutics

Our reporting

Next results

17 Mar 2027

Due on 17 Mar 2027. Analysts expect earnings of -0.16 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Dogwood Therapeutics's ticker?

Dogwood Therapeutics trades as DWTX on its US listing, under ISIN US92829J2033.

What was Dogwood Therapeutics's last closing price?

1.06 on 19 Nov 2026. The figure is in USD and is never converted.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.